Table 2 |
||||||
| Plasma concentrations of ABT-116, carprofen, tramadol, and placebo before and after the first and last doses of the treatment period | ||||||
| Treatment group | Trial day 8 | Trial day 22 | ||||
| Before dosing | 3 hours after dosing | n | Before dosing | 3 hours after dosing | n | |
| ABT-116 | 0 ± 0 | 569 ± 294 | 12# | 1,277 ± 644 | 1,589 ± 700*** | 12# |
| ABT-116 metabolite | 0 ± 0 | 115 ± 63 | 11# | 592 ± 256 | 538 ± 244*** | 11# |
| Carprofen | 0 ± 0 | 3,386 ± 2,282 | 11# | 3,752 ± 2,211 | 4,779 ± 2,789 | 11# |
| Tramadol | 0.0 ± 0.0 | 39.3 ± 35.3 | 11# | 0.6 ± 1.9 | 7.1 ± 8.8** | 11# |
Note: All values represent mean ± standard deviation in ng/ml. n – sample number. #One dog in the treatment group was excluded because high drug concentrations were detected in the pre-treatment sample and low concentrations in one or more post-treatment samples. ABT-116, Carprofen, and Tramadol were not detected in any plasma sample from the Placebo group. Significance of changes in plasma drug concentrations from post-treatment sample on Day 8 is indicated as follows: ** - P < 0.01; *** - P < 0.001.
Malek et al. BMC Veterinary Research 2012 8:185 doi:10.1186/1746-6148-8-185
